Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mapi Pharma, Mylan Expand MS Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Mapi Pharma, Mylan Expand MS Alliance

Mylan to invest an additional $20M in Mapi to support progress in Phase III trials of once-monthly Glatiramer Acetate Depot for RRMS

By: Contract Pharma

Contract Pharma Staff

Mapi Pharma Ltd. received an additional $20 million investment from Mylan to support Phase III clinical study progress to bring Glatiramer Acetate (GA) Depot, a once-monthly injection for the treatment of relapsing-remitting multiple sclerosis (RRMS), to market in the U.S.

Mapi initiated the Phase III study in October and is a 1,000 patient pivotal clinical study designed to support a New Drug Application (NDA) with the FDA. Mapi is also building capacity at its facility to supply GA-Depot for commercial sale, pending approval.

In the U.S., a study funded by the National MS Society estimates that nearly 1 million people are living with MS. Relapsing-remitting MS accounts for approximately 85% of initial MS diagnoses. According to recent market research, the global multiple sclerosis drugs market is anticipated to expand at a CAGR of 6.7%, and reach $39 billion by the end of 2026.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics